Suchen
HCW Biologics Inc
HCWBZur Watchlist hinzufügen
1.070USD
+0.733+217.57%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
2.81MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über HCW Biologics Inc Unternehmen
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
HCW Biologics Inc Informationen
BörsenkürzelHCWB
Name des UnternehmensHCW Biologics Inc
IPO-datumJul 20, 2021
CEOWong (Hing C)
Anzahl der mitarbeiter36
WertpapierartOrdinary Share
GeschäftsjahresendeJul 20
Addresse2929 N Commerce Pkwy
StadtMIRAMAR
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl33025
Telefon19548422024
Websitehttps://hcwbiologics.com/
BörsenkürzelHCWB
IPO-datumJul 20, 2021
CEOWong (Hing C)
Führungskräfte von HCW Biologics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
501.91K
--
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
--
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
25.50K
--
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
5.72K
+16.82%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
1.94K
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
--
Mr. Rick S. Greene
Mr. Rick S. Greene
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
501.91K
--
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
--
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
25.50K
--
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
5.72K
+16.82%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
1.94K
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Thu, May 14
Aktualisiert: Thu, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Wong (Hing C)
7.45%
Armistice Capital LLC
4.46%
Byam (Rebecca)
0.64%
DRW Securities, LLC
0.52%
Garrett (Scott T)
0.38%
Andere
86.55%
Aktionäre
Aktionäre
Anteil
Wong (Hing C)
7.45%
Armistice Capital LLC
4.46%
Byam (Rebecca)
0.64%
DRW Securities, LLC
0.52%
Garrett (Scott T)
0.38%
Andere
86.55%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
8.69%
Hedge Fund
4.85%
Investment Advisor
1.61%
Investment Advisor/Hedge Fund
0.21%
Research Firm
0.01%
Andere
84.63%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
39
465.64K
6.91%
+303.62K
2025Q4
36
125.21K
4.63%
+21.18K
2025Q3
35
36.93K
1.72%
-55.99K
2025Q2
40
613.16K
31.10%
+79.16K
2025Q1
40
480.61K
42.86%
-46.33K
2024Q4
37
23.10M
51.86%
+2.14M
2024Q3
33
21.13M
54.31%
+156.07K
2024Q2
33
21.19M
54.45%
+322.27K
2024Q1
34
20.93M
57.88%
+1.69M
2023Q4
33
19.30M
53.71%
+122.06K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Wong (Hing C)
501.91K
14.27%
--
--
Feb 17, 2026
Armistice Capital LLC
300.18K
8.54%
+300.18K
--
Dec 31, 2025
Byam (Rebecca)
43.01K
1.22%
--
--
Feb 17, 2026
DRW Securities, LLC
35.28K
1%
-48.16K
-57.71%
Dec 31, 2025
Garrett (Scott T)
25.50K
0.73%
--
--
Feb 17, 2026
Citadel Advisors LLC
22.16K
0.63%
+22.16K
--
Dec 31, 2025
Susquehanna International Group, LLP
20.07K
0.57%
+20.07K
--
Dec 31, 2025
Abante Asesores Gestión, S.G.I.I.C., S.A.
19.80K
0.56%
+19.80K
--
Dec 31, 2025
Geode Capital Management, L.L.C.
14.04K
0.4%
+3.04K
+27.60%
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Apr 01, 2025
Merger
40→1
Datum
Ex-Dividendentag
Art
Verhältnis
Apr 01, 2025
Merger
40→1
